糖尿病黄斑水肿与二极管阈下微脉冲激光:一项随机双盲非劣效性临床试验
该实用型多中心双盲随机非劣效性试验纳入266例中心受累型糖尿病黄斑水肿且中央视网膜厚度<400 μm的成人患者,比较577 nm阈下微脉冲激光与标准激光的疗效与安全性。24个月时,阈下微脉冲激光组最佳矫正视力平均下降2.43±8.20个ETDRS字母,标准激光组下降0.45±6.72个ETDRS字母,组间差值的95%CI(-3.9至-0.04个字母)完全落在预设非劣效界值5个字母之内,判定为等效,但阈下微脉冲激光组所需激光治疗次数略多。
要点
- 24个月时阈下微脉冲激光组BCVA较基线下降2.43±8.20个ETDRS字母,标准激光组下降0.45±6.72个字母。
- 组间BCVA差值95%CI为-3.9至-0.04个ETDRS字母,完全落在±5个字母非劣效界值内,判定为等效。
- 阈下微脉冲激光组激光治疗次数多于标准激光组(差值0.48次,95%CI 0.18-0.79,P=0.002)。
核心结论
- 阈下微脉冲激光治疗与标准激光治疗等效,但需要略多的激光治疗次数。
研究设计与样本
- 实用型、多中心、分配隐藏、双盲、随机、非劣效性试验。
- 共纳入266例成人患者,为中心受累型糖尿病黄斑水肿且中央视网膜厚度<400 μm、研究眼或双眼最佳矫正视力>24个ETDRS字母者。
- 按1:1随机分配至577 nm阈下微脉冲激光组或标准激光组,允许重复治疗;若出现视力下降≥10个ETDRS字母或中央视网膜厚度增至>400 μm或两者兼有,允许使用玻璃体内抗血管内皮生长因子药物或类固醇进行补救治疗。
- 主要结局为24个月时研究眼最佳矫正视力平均变化,非劣效界值为5个ETDRS字母。
主要发现
- 24个月时,阈下微脉冲激光组最佳矫正视力较基线变化为-2.43±8.20个ETDRS字母,标准激光组为-0.45±6.72个ETDRS字母。
- 组间最佳矫正视力变化差值的95%CI为-3.9至-0.04个ETDRS字母,完全落在允许的最大差值5个ETDRS字母的上下界之内,判定为非劣效且等效。
- 双眼最佳矫正视力组间差异为0.32个ETDRS字母(95%CI -0.99至1.64,P=0.63),无统计学显著差异。
- 中央视网膜厚度组间差异为-0.64 μm(95%CI -14.25至12.98,P=0.93),视野平均偏差组间差异为0.39 dB(95%CI -0.23至1.02,P=0.21),均无统计学显著差异。
- 达到驾驶标准百分比组间差异为1.6个百分点(95%CI -25.3%至28.5%,P=0.91),不良反应风险比为0.28(95%CI 0.06-1.34,P=0.11),补救治疗百分比组间差异为-2.8个百分点(95%CI -13.1%至7.5%,P=0.59),EQ-5D、NEI-VFQ-25及VisQoL评分均无统计学显著差异;阈下微脉冲激光组激光治疗次数更多(差值0.48次,95%CI 0.18-0.79,P=0.002)。
关键数值与推荐
- 非劣效界值为5个ETDRS字母,主要结局组间差值95%CI为-3.9至-0.04个ETDRS字母,完全落在界值内。
- 阈下微脉冲激光组激光治疗次数较标准激光组多0.48次(95%CI 0.18-0.79,P=0.002)。
- 补救治疗条件为视力下降≥10个ETDRS字母或中央视网膜厚度增至>400 μm或两者兼有。
临床怎么用
- 对于中心受累型糖尿病黄斑水肿且中央视网膜厚度<400 μm的患者,阈下微脉冲激光治疗与标准激光治疗等效,但需要略多的激光治疗次数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine clinical effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 μm. DESIGN: Pragmatic, multicenter, allocation-concealed, double-masked, randomized, noninferiority trial. PARTICIPANTS: Adults with center-involved DME < 400 μm and best-corrected visual acuity (BCVA) of > 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in one/both eyes. METHODS: Randomization 1:1 to 577 nm SML or SL treatment. Retreatments were allowed. Rescue with intravitreal anti-vascular endothelial growth factor therapies or steroids was permitted if 10 or more ETDRS letter loss occurred, CRT increased > 400 μm, or both. MAIN OUTCOME MEASURES: Primary outcome was mean change in BCVA in the study eye at 24 months (noninferiority margin 5 ETDRS letters). Secondary outcomes were mean change from baseline to month 24 in binocular BCVA; CRT and mean deviation of Humphrey 10-2 visual field in the study eye; percentage meeting driving standards; EuroQoL EQ-5D-5L, 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), and Vision and Quality of Life Index (VisQoL) scores; cost per quality-adjusted life-years (QALYs) gained; adverse effects; and number of laser and rescue treatments. RESULTS: The study recruited fully (n = 266); 87% of SML-treated and 86% of SL-treated patients had primary outcome data. Mean ± standard deviation BCVA change from baseline to month 24 was -2.43 ± 8.20 letters and -0.45 ± 6.72 letters in the SML and SL groups, respectively. Subthreshold micropulse laser therapy was deemed not only noninferior but also equivalent to SL therapy because the 95% confidence interval (CI; -3.9 to -0.04 letters) lay wholly within both upper and lower margins of the permitted maximum difference (5 ETDRS letters). No statistically significant difference was found in binocular BCVA (0.32 ETDRS letters; 95% CI, -0.99 to 1.64 ETDRS letters; P = 0.63); CRT (-0.64 μm; 95% CI, -14.25 to 12.98 μm; P = 0.93); mean deviation of the visual field (0.39 decibels (dB); 95% CI, -0.23 to 1.02 dB; P = 0.21); meeting driving standards (percentage point difference, 1.6%; 95% CI, -25.3% to 28.5%; P = 0.91); adverse effects (risk ratio, 0.28; 95% CI, 0.06-1.34; P = 0.11); rescue treatments (percentage point difference, -2.8%; 95% CI, -13.1% to 7.5%; P = 0.59); or EQ-5D, NEI-VFQ-25, or VisQoL scores. Number of laser treatments was higher in the SML group (0.48; 95% CI, 0.18-0.79; P = 0.002). Base-case analysis indicated no differences in costs or QALYs. CONCLUSIONS: Subthreshold micropulse laser therapy was equivalent to SL therapy, requiring slightly higher laser treatments.
引用
- Lois N, Campbell C, Waugh N, et al. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Ophthalmology. 2022. PMID: 35973593. doi:10.1016/j.ophtha.2022.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。